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Abstract
Traumatic brain injury (TBI) is a leading cause of death and disability globally. No drug treatments are available, so
interest has turned to endogenous neural stem cells (NSCs) as alternative strategies for treatment. We hypoth-
esized that regulation of cell proliferation through modulation of the sonic hedgehog pathway, a key NSC reg-
ulatory pathway, could lead to functional improvement. We assessed sonic hedgehog (Shh) protein levels in the
cerebrospinal fluid (CSF) of patients with TBI. Using the cortical contusion injury (CCI) model in rodents, we used
pharmacological modulators of Shh signaling to assess cell proliferation within the injured cortex using the
marker 5-Ethynyl-2’-deoxyuridine (EdU); 50mg/mL. The phenotype of proliferating cells was determined and
quantified. Motor function was assessed using the rotarod test. In patients with TBI there is a reduction of
Shh protein in CSF compared with control patients. In rodents, following a severe CCI, quiescent cells become
activated. Pharmacologically modulating the Shh signaling pathway leads to changes in the number of newly
proliferating injury-induced cells. Upregulation of Shh signaling with Smoothened agonist (SAG) results in an in-
crease of newly proliferating cells expressing glial fibrillary acidic protein (GFAP), whereas the Shh signaling in-
hibitor cyclopamine leads to a reduction. Some cells expressed doublecortin (DCX) but did not mature into
neurons. The SAG-induced increase in proliferation is associated with improved recovery of motor function.
Localized restoration of Shh in the injured rodent brain, via increased Shh signaling, has the potential to sustain
endogenous cell proliferation and the mitigation of TBI-induced motor deficits albeit without the neuronal
differentiation.
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Introduction
Traumatic Brain Injury (TBI) accounts for half of
injury-induced deaths1 worldwide and is expected to
increase over the next decade. With no effective restor-
ative therapies currently available,2,3 interest has turned
toward neural stem cells (NSCs)/progenitor cells, as
they can dynamically sense the injured microenviron-
ment, and can respond with a multitude of restorative
factors that alter the injury milieu. Targeting the en-
dogenous NSCs by altering them to modify the injury
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milieu4 may improve the outcome after TBI. Therefore,
understanding the NSC response to TBI has the poten-
tial to identify new therapeutic strategies for the treat-
ment of TBI.
Endogenous neurogenesis occurs in the hippocam-
pus and the subventricular zone (SVZ) throughout
life.5,6 Quiescent precursor cells are present in non-
permissive regions of the nervous system such as the
cortex of rodents7–10 and humans.11 Within these re-
gions, a TBI induces neurogenesis of the normally qui-
escent precursor cells.12–14 Using an organotypic
stretch injury model for TBI, we have shown that
after injury equivalent to a severe TBI, a subset of en-
dogenous cells acquired stem cell properties in the in-
jured cortex.12 These cells were endogenous to the
cortex; they did not migrate from the SVZ.
Injury activates a population of endogenous cells
that display NSC properties. However, to harness
these cells for repair, the mechanistic pathways that
contribute to the process need to be determined.
Manipulation of these pathways alters the proliferation
of the NSCs, which could lead to improved function.
Previously, we demonstrated a transient upregulation
of sonic hedgehog (Shh) signaling pathway compo-
nents in the injured cortex. This was linked with the ac-
quisition of stem cell properties of a subset of cells in
the injured cortex.20 Shh is a member of the hedgehog
family of secreted signaling proteins and has a role in
adult stem cell proliferation. In rodents, Shh signal-
ing is active in cells that give rise to neurogenesis in
the hippocampus15,16 and SVZ.17–19 Adult quiescent
NSCs proliferate faster in response to Shh20 and applica-
tion of Shh leads to de novo neurogenesis in neocortex of
adult mice.21 In addition to increasing neurogenesis, Shh
improves neurite outgrowth of neurons growing on a
monolayer of reactive astrocytes.22 Thus, Shh acts as a
positive regulator of cell proliferation, neurogenesis,
and neuronal maturation.
The significance of Shh signaling after injury has
been demonstrated. For example, following ischemia
there is an increase of Shh in the brain,23 and intrathe-
cal administration of Shh in a stroke model has shown
a neuroprotective effect.24 Similarly, Shh signaling is
upregulated in reactive astrocytes following a focal
freeze injury to the cerebral cortex.25 Moreover, this ex-
pression contributes to an increase in the proliferation
of a subset of progenitor cells,25 suggesting that Shh sig-
naling in the injured cortex directly influences precur-
sor cells. In an in vitro model of a cortical astrocytic
glial scar, stretch injury leads to impaired neurite out-
growth of neurons placed upon the stretched astrocytic
layer, and this was reversed by the addition of Shh.22 We
have shown in our in vitro cortico-hippocampal model
that a stretch injury increases expression of components
of the Shh signaling pathway.12 Therefore, we hypothe-
sized that Shh signaling may contribute to the injury-
induced cell proliferation and NSC activation seen
following a severe cortical contusion injury (CCI).
Here, we have demonstrated that in patients with
TBI, there is a reduction of Shh protein in cerebrospi-
nal fluid (CSF) compared with control patients. In a ro-
dent in vivo CCI head injury model, we demonstrated
that increasing Shh signaling after injury increases the
number of newly proliferating cells in the cortex. This
is accompanied by improvement in motor function in
rodents. Thus, manipulating the niche environment
of the non-permissive injured brain, by increasing
Shh signaling, may lead to strategies for endogenous
neural repair and subsequent functional recovery.
Methods
Shh ELISA in human CSF
CSF samples were collected from patients with severe
TBI in which an external ventricular drain was placed
for the management of the patient’s head injury. Sam-
ples were taken from control patients undergoing rou-
tine lumbar puncture for neurological investigations,
the results of which were normal. Samples were stored
at 80C until analyzed. The Shh concentration was
determined by enzyme-linked immunosorbent assay
(ELISA; Human Shh N-terminus Quantikine ELISA
Kit, DSHH00, Bio-Techne) according to the manufac-
turer’s instructions. All samples were obtained with in-
formed consent and according to guidelines of the
National Research Ethics Committee (10/H0502/53).
Human tissue polymerase chain reaction (PCR)
Normal cortical tissue was resected from five patients
during access for epilepsy or tumor surgery. All pa-
tients provided informed consent for participation
and the human brain tissue samples were anonymized.
Ethical approval was obtained from the Research Ethics
Committee (12/NW/0 794 and 07/H0504/195). In
three cases, hippocampal tissue was also taken from
the same patient.
Tissue was transferred in ice-cold artificial CSF
(aCSF) and placed directly into TRIzol (Invitrogen).
Total RNA was extracted and directly reverse-
transcribed to complementary DNA (cDNA) using a
Precision qScript RT Kit (Primer Design). The cDNA
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was amplified using a One-Step PCR Kit (Primer
Design) in a real-time thermocycler (Rotor-Gene
6000, Corbett Robotics). Custom-made primers were
directed against human Shh, Patched1, and Smooth-
ened (Primer Design; Table 1). Fluorescent data were
collected at least once during each cycle of amplifica-
tion, which allowed for real-time monitoring of the
amplification. Data were automatically normalized
and a threshold was set at the level where the rate of
amplification was the greatest during the exponential
phase. Ct-values were collected, and analyzed using
the comparative Ct (2[-Delta Delta C(t)], or 2-DDCt)
method where the comparative expression level equals
to 2-DDCt. The expression of messenger RNA (mRNA)
was normalized to a housekeeping gene (b-actin) and
expressed as a ratio. Prism Software (Graphpad) was
used for data analysis.
The CCI injury and drug treatment
C57Bl/6 mice (20–25 g, 7–8 weeks old) were housed in
a 12-h light/dark cycle with food and water ad libitum.
All animal procedures followed guidelines established
by the National Institutes of Health (NIH) Guide for
the Care and Use of Laboratory Animals, Animal
Research: Reporting of In Vivo Experiments
(ARRIVE), and were approved by the University of Mi-
ami’s Institutional Animal Care and Use Committees
(Protocol Number 14-157).
The statistical ‘‘power’’ methods were used to arrive at
the appropriate sample size with a power of 0.9 at a 0.05
alpha. A minimum of 10 animals were used in each group
for the behavioral analysis and a minimum of 5 animals in
each group for the histological analysis. Mice were anes-
thetized with ketamine (75 mg/kg) and xylazine
(14 mg/kg) by intraperitoneal injection and positioned
in a stereotaxic frame. Body temperature was monitored
and maintained at 37C. A 5-mm craniotomy was
made over the right parieto-temporal cortex (2.5 mm
caudal and 2.0 mm lateral from bregma). The injury
was generated using a 3-mm beveled tip attached to a
CCI device (Custom Design & Fabrication), at a velocity
of 6.0 m/sec, a depth of 0.5 mm, and an impact duration
of 150 msec. Sham mice received craniotomy only. After
CCI injury the skin was sutured. Starting on the day of
injury, mice received the following: 1 — cyclopamine
treated animals received intra-peritoneal injection of
cyclopamine (10 mg/kg, Sigma Aldrich) diluted in
hydroxypropyl beta cyclodextrin (HBC; Sigma Aldrich)
once a day for 5 days; 2 - control animals received
intra-peritoneal injection of HBC only once a day for 5
days; 3 SAG treated animals received oral administration
of SAG (Calbiochem; 0.15 mg in 0.5% methylcellulose/
0.2% Tween 80/10 g body weight) once a day for 5 days.
Behavior
Motor function was tested using the rotarod test. The
rotating cylindrical rod was 50-mm wide and had a lin-
ear acceleration from 10 rpm to 60 rpm over a period of
10 min (i.e., rate of acceleration was 5 rpm). Mice were
pre-trained daily for 1 week prior to the injury. After
injury on days 3, 7, and 14, mice were given four trials
each day and the time to fall off the rotarod was aver-
aged over the four trials.
Immunohistochemistry of free-floating sections
Mice were anesthetized using ketamine and xylazine by
intraperitoneal injection and transcardially perfused
with phosphate-buffered saline (PBS) and 4% parafor-
maldehyde (pH 7.4). Animals were sacrificed at 7, 14,
and 28 days after injury. The brains were stored in
4% paraformaldehyde overnight, 30% sucrose for
48 h, and then transferred into PBS with 0.5% sodium
azide. The brains were then sliced coronally around the
injury site using a cryostat into 40-lm thick sections.
Serial free-floating sections were collected in a 12-
well plate. There were approximately four to five free-
floating sections that traversed the injury site in each
well. The sections were kept in a PBS and 0.5% sodium
azide solution at 4C.
EdU detection was performed using the Click-iT
EdU Alexa Fluor 594 Imaging Kit following the man-
ufacturer’s instructions (C10399, Invitrogen). Sections
were subsequently labeled with either GFAP (rabbit,
Dako), nestin (mouse, VectorLabs), or DCX (guinea
pig, Millipore) pre-diluted in 0.3% Triton X-100 in
PBS with 5% donkey serum, with overnight incubation
at 4C. Fluorescent secondary antibodies (Alexa488,
Molecular Probes) were incubated for 2 h before further
washes. Nuclei were labeled with Hoechst 33342 solu-
tion (diluted PBS) before mounting in Mowiol (Harco).
Table 1. PCR Primer Sequences




Primer sequences for RT-qPCR in human neural tissue. Beta-actin
primers were obtained from Primer Design (HK-SY-HU-600, ACTB).
PCR, polymerase chain reaction; Ptc, Patched; Shh, sonic hedgehog;
Smo, Smoothened.




Cells were imaged at 20 · magnification using a Hama-
matsu Orca 1-megapixel CCD camera fitted to a Leica
DMIRBE microscope. Images were captured and ana-
lyzed using Volocity (Improvision). Four fields were se-
lected at consistent areas of the peri-lesional region
corresponding to each corner of the injury site in
each of the sections using standard DAPI, fluorescein,
and Rhodamine filter sets. To quantify the cell num-
bers, a 200-lm · 200-lm (40,000 lm2) square grid
was placed at random within each of the four fields
around the peri-lesional area. Cell counts were
obtained in each area for Hoechst, EdU, GFAP, and
double-labeled cells per 40,000-lm2 grid. For three
brains in each group at least three sections containing
the injury site were analyzed. All images for presenta-
tion were taken with a Leica SP5 confocal microscope.
Statistical analysis
A mixed analysis of variance (ANOVA) model was
used to analyze data obtained from the rotarod
motor test. Our ANOVA model used treatment groups
(SAG, cyclopamine, and control) as a between-subjects
factor, and days post-injury (dpi; 0, 3, 7, 14, and 28 dpi)
as a within-subjects factor. Mauchly’s test was used to
evaluate model sphericity. The Bonferroni correction
method was used to allow for repeated measures anal-
ysis. Independent-samples t tests were conducted to
study the effect at each time-point. Statistical analyses
were completed in IBM SPSS (version 22.0.0.0). Results
from the histological studies were analyzed using the
Graphpad Prism stats package. Statistical significance
was assessed using one-way ANOVA or Kruskal-
Wallis test, followed by appropriate post hoc tests.
Results
Shh protein levels decrease in the CSF of patients
with severe TBI
There are limited data on the level of Shh in the human
central nervous system. To determine if Shh levels were
altered by TBI, we compared the concentration of Shh
protein in the CSF of patients requiring an external
ventricular drain (EVD) following a severe TBI (Glas-
gow Coma Scale score <8, with raised intracranial pres-
sure necessitating an EVD to relieve that pressure) with
CSF of non-TBI patients. CSF from patients with TBI
was obtained at a median of 1.5 days from injury (me-
dian, 1.5 days; range, 0–3 days). In patients with TBI,
the level of Shh in CSF was significantly lower com-
pared with uninjured control patients (10.5 pg/mL vs.
483.1 pg/mL; p < 0.01, Mann-Whitney U test; Fig. 1).
Next, we demonstrated that human cortical cells
contain Shh signaling components. Patients undergo-
ing either epilepsy surgery or tumor surgery had
resected ‘‘normal’’ access tissue frozen and analyzed.
Human cDNA from cortical and hippocampal tissue
demonstrated expression of Shh and its receptors
Smoothened and Patched1. Expression of all three
genes was demonstrated in both brain regions with
no significant difference in levels between cortex or
hippocampus (Table 2).
FIG. 1. Shh is reduced in CSF following TBI in
human patients. CSF was collected from external
ventricular drains in patients who had suffered a
severe TBI or from a control group undergoing
routine lumbar puncture. The concentration of
Shh was determined by ELISA and was
significantly lower in patients with TBI compared
with the control group. Graph shows distribution
of the data with the median indicated by the
horizontal bars (control, n = 7; TBI, n = 14;
**p < 0.01). CSF, cerebrospinal fluid; ELISA,
enzyme-linked immunosorbent assay; Shh, sonic
hedgehog; TBI, traumatic brain injury.
Table 2. Human PCR
Cortex Hippocampus
Shh 10.26 – 1.46 9.33 – 1.29
Smo 9.90 – 1.44 9.20 – 1.42
Ptc 9.63 – 0.68 9.30 – 0.44
Relative expression of Shh, Smo, and Ptc in cortex (n = 5) and hippo-
campus (n = 3) from adult human brain. Expression of all three genes oc-
curs in both brain regions, with no significant difference observed.
PCR, polymerase chain reaction; Ptc, Patched; Shh, sonic hedgehog;
Smo, Smoothened.
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Increasing Shh signaling results in increased
cell proliferation
We previously demonstrated that in mice, the mRNA
of Shh signaling components is increased after injury.12
We therefore sought to determine if the increase in cell
proliferation post-injury could be modulated by Shh
signaling. Proliferating GFAP-positive (GFAP+) cells
may represent either reactive astrocytes or NSCs. CCI
induces ipsilateral cells to acquire NSC-like properties
in vivo, including proliferation to form neurospheres
and differentiation to astrocytes, oligodendrocytes,
and neurons (Supplementary Appendix S1; Supple-
mentary Figs. S1 and S2). Following a CCI, animals
were treated either with the Shh antagonist cyclop-
amine or the Shh agonist SAG. The phenotype of
injury-induced proliferating (EdU+) cells was investi-
gated. Significant numbers of GFAP+ cells were ob-
served up to 28 dpi (Figs. 2 and 3A). At 7 dpi, the
total number of GFAP+ cells were significantly in-
creased in SAG-treated animals, and reduced in
cyclopamine-treated animals (Fig. 3B, p < 0.05), but
this effect was lost by 14 dpi. Although changes in the
total number of GFAP+ cells give an indication of the
effect of SAG and cyclopamine, the total number of
cells (Hoescht+) is also affected in each condition.
A more accurate reflection is to consider the propor-
tion of the total number of cells that are GFAP+
(GFAP+/Hoescht+). This increased with SAG and de-
creased with cyclopamine ( p < 0.05; Fig. 3B).
To determine the number of new injury-induced
cells, EdU+ cells were quantified. After 7 dpi, SAG sig-
nificantly increased proliferation when compared with
the control injury group, whereas cyclopamine de-
creased proliferation (Fig. 3C, p < 0.01). Both of these
effects were transient, with no effect of either com-
pound observed at 14 dpi or 28 dpi (Fig. 3C). The pro-
portion of the total cells that were proliferating (the
mitotic index, Edu+/Hoescht+) was significantly re-
duced with cyclopamine treatment at 7 dpi ( p < 0.05),
whereas SAG had no effect (Fig. 3D).
To determine the phenotype of the EdU+ cells, we
investigated the cells that co-expressed GFAP and
Edu (EdU+GFAP+) because some of these cells may
represent the NSC population within the cortex. We
observed a significant increase in the total number of
EdU+GFAP+ cells and the proportion of the total
number of GFAP cells that were newly proliferating
(EdU+GFAP+/Hoescht+) at 7 dpi in SAG-treated
mice ( p < 0.001). This effect was transient, being lost
at 14 dpi and 28 dpi. No significant effect of cyclop-
amine was observed, although there was a downward
trend at 7 dpi (Fig. 3E).
FIG. 2. Example images demonstrating injury-induced proliferation in the cortex 7 dpi after CCI. (A–D) In the
uninjured (contralateral) cortex, DAPI+ cell nuclei are present (A), but there were negligible GFAP+ (B) or EdU+
(C) cells. (D) is a composite of A–C. However, in the area surrounding the injury (ipsilateral cortex), GFAP+ cells
and processes were clearly detectable. Proliferating cells, as indicated by EdU staining were also clearly
detectable (G). (H) A composite of E–G and demonstrates that GFAP and EdU staining co-localize in some
cells (solid arrows), whereas other cells express GFAP only (dotted arrow). Scale bar = 50 lm. CCI, cortical
contusion injury; dpi, days post-injury; EdU, 5-Ethynyl-2’-deoxyuridine; GFAP, glial fibrillary acidic protein.
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Although early-stage proliferating neural stem/
progenitor cells would be expected to be double labeled
with EdU and GFAP, this is not a definitive marker. As
such, we also investigated the number of newly prolif-
erating cells that expressed the intermediate filament
protein nestin. However, at both 7 dpi and 14 dpi, the
number of nestin+ cells was low in CCI-injured ani-
mals (1.4 – 0.6 cells per field at 7 dpi; 1.2 – 0.84 cells/
field at 14 dpi), with even fewer cells visible in the
SAG or cyclopamine groups.
Effect of Shh signaling on doublecortin
(DCX) expression
NPCs that move from transiently amplifying progenitor
cells toward a more mature neuronal phenotype will
downregulate nestin expression, as they gradually express
the early neuronal protein DCX.26 We therefore deter-
mined the number of DCX+ cells at 7 and 14 days
post-injury. At 7 dpi, DCX+ cells were observed in the
peri-lesional area in the control injury group (26.5 – 5.8
cells/area), but not in the SAG (0.1 – 0.1 cells, p < 0.01
vs. control) or cyclopamine (1.1 – 0.6; p < 0.01 vs. control)
groups. By 14 days, there was a significant decrease in the
number of DCX+ cells in the control injury group
(2.9 – 2.7 cells, p < 0.001 vs. 7 dpi control) with no expres-
sion in either the SAG or cyclopamine groups (Fig. 4A
and Fig. 5).When considering the number of DCX+
cells maturing during the peri-lesional period, we deter-
mined the number of cells that were double-labeled for
both DCX and EdU. Double-labeled cells were observed
in the control injury group at 7 dpi (7.6 – 1.7), but not in
the SAG (0 – 0, p < 0.01 vs. control) or cyclopamine
(0.3 – 0.2, p < 0.01) treated animals. By 14 dpi, the num-
ber of double-labeled cells in the control injury group
was reduced (0.6 – 0.6, p < 0.01 vs. 7 dpi control; Fig. 4B).
Activation of Shh pathway improves
functional recovery
We next sought to determine if the transient mainte-
nance of GFAP cells with Shh agonists improved
motor function. Motor function was assessed using a
rotarod system on which mice had been trained daily
for 7 days prior to injury. The mean latency scores
after training were equivalent between groups
(115 – 6 sec, control; 125 – 12 sec, SAG; 110 – 9 sec,
cyclopamine). In control CCI, motor performance
was significantly impaired (61 – 9 sec) 3 days after
CCI compared with baseline, with a partial recovery
by 14 dpi (88 – 1 sec). A similar pattern was observed
in mice treated with cyclopamine, although there was
‰
FIG. 3. Shh signaling post-injury enhances NSC proliferation. (A) GFAP+ (G+) cells were observed in the
cortex ipsilateral to the injury (control, SAG, and cyclopamine), but not in the contralateral cortex. In
control brains, the number of G+ cells remained unchanged 7–28 days post-injury. At 7 days post-injury
there was a significant increase in G+ cells in SAG-treated mice. The opposite effect occurred with
cyclopamine treatment. The effect of SAG was reversed by 28 days with a significant decrease in G+ cells
being observed. (B) A similar effect of cyclopamine was observed when the proportion of GFAP+ cells
(G+/H+) was considered, with a reduction in G+/H+ cells occurring at 7 and 28 dpi. In SAG-treated mice, an
increase was observed at 14 days post-injury, with no significant effect observed at other time-points.
(C) The number of proliferating cells was detected by positive EdU labeling (E+). E+ cells were only
observed on the side ipsilateral to the injury. SAG induced an increase in E+ cells 7 days post-injury, an
effect that was transient and was lost by 14 days post-injury. Conversely, cyclopamine resulted in a
decrease in proliferation at 7 days but not later. (D) The proportion of E+ cells (E+/H+) was decreased at 7
days by cyclopamine, with no effect at later time-points. There was no significant effect of SAG at any
time-point. (E) Proliferating NSCs will be both GFAP+ and EdU+ (E+G+). Small numbers of E+G+ cells were
detected in the ipsilateral cortex. SAG treatment significantly increased the number of E+G+ cells at 7 dpi,
an effect that was lost by later time-points. No effect of cyclopamine on E+G+ cells was seen. (F) SAG
treatment also increased the proportion of E+G+ cells (E+G+/H+) at 7 days post-injury but not at later
time-points. Cyclopamine had no effect on the number of E+G+ cells. (n = 4–11; *p < 0.05, **p < 0.01,
***p < 0.001 vs. control injury). dpi, days post-injury; EdU, 5-Ethynyl-2’-deoxyuridine; GFAP, glial fibrillary
acidic protein; NSC, neural stem cell; SAG, Smoothened agonist; Shh, sonic hedgehog.
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a trend toward a reduction in recovery with cyclop-
amine. In contrast, SAG treatment resulted in signifi-
cantly improved recovery at 3 dpi (91 – 18 sec)
followed by recovery to baseline levels after 7 and
14 dpi (Fig. 6). This suggests that modulation of Shh
signaling alters motor recovery post-injury.
Discussion
Following a CCI, we demonstrated an overall increase
in GFAP-expressing cells ipsilateral to the injury. In a
previous in vitro study, we demonstrated that a propor-
tion of these cells are stem/progenitor cells.12 The Shh
receptor, Patched1, was upregulated following injury,
33
suggesting that Shh signaling may be important in reg-
ulating the proliferation of injury-induced GFAP cells.12
In this study, using pharmacological modulators of Shh
we demonstrated that activating Shh signaling tran-
siently increases the number of newly proliferating
GFAP cells on the injured side, while inhibiting Shh re-
duces cell proliferation. This suggests that modulating
Shh results in changes in the number of injury-induced
GFAP cells, and we know from our previous work that a
proportion of these injury-induced proliferating cells are
NSCs. The GFAP+ cells could be referred to as ‘‘reactive
astrocytes’’ and NSCs can be derived from mature astro-
cytes.8 To clarify if these injury-induced GFAP+ cells are
different to reactive astrocytes, future studies with cell-
type specific reporters, such as nestin or DCX reporter
mice, could be used. This would objectively assess the
fate of proliferating cells induced by TBI, complement-
ing our histological work.
In line with our findings, several injury models dem-
onstrate an increase in progenitor cells following the in-
jury, and this has been shown to be augmented by the
Shh agonist SAG. For instance, in a stab injury model,
SAG results in an increase in the number of newly pro-
liferating GFAP+ cells.27 Similarly, following an ischemic
FIG. 4. Modulation of DCX expression by CCI. (A) The number of DCX+ cells in the peri-injury area was
determined by immunohistochemistry 7 days and 14 days after CCI. Following injury alone (control), DCX+
cells were observed in the cortex around the injury 7 days later. By 14 days after injury, the number of
DCX+ cells had significantly declined. In mice treated with either SAG or cyclopamine, the number of DCX-
positive cells was significantly lower than in control injury mice at 7 days post-injury. (B) DCX+ cells derived
from proliferating cells were double-labeled with EdU (DCX+EdU+). A small number of DCX+EdU+ cells
were found in the cortex around the lesion 7 dpi. As with the DCX+ cells, the number of DCX+EdU+
significantly declined by 14 dpi. Similarly, the number of DCX+EdU+ cells at 7 dpi was significantly lower in
mice treated with either SAG or cyclopamine. (n = 3, ++p < 0.01 vs. control; **p < 0.01 vs. 7 day control;
***p < 0.001 vs. control). CCI, cortical contusion injury; dpi, days post-injury; DCX, doublecortin; . EdU, 5-
Ethynyl-2’-deoxyuridine; SAG, Smoothened agonist.
FIG. 5. Images showing both DCX+ and DCX+EdU+ cells in the cortex 7 dpi. (A) DAPI-staining of cell
nuclei (blue); (B) immunohistochemistry for DCX (green); (C) EdU staining (red); (D) composite image
indicating cell labeled with DCX only (dashed arrow) or double-labeled with DCX and EdU (solid arrow).
Scale bar = 50 lm. dpi, days post-injury; DCX, doublecortin; EdU, 5-Ethynyl-2’-deoxyuridine.
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stroke, progenitors from the SVZ migrating into the is-
chemic tissue are increased following SAG treatment.28
Therefore, in models of injury that lead to cells acquiring
stem-like properties at the injury site, activation of Shh
signaling by SAG acts to increase the stem/progenitor re-
sponse. Similarly, migrating GFAP-expressing NSCs
from the SVZ are regulated by Shh, and manipulation
of the Shh pathway alters the fate of these cells.17 This
implies that there is a common mechanism of NSC ac-
tivation by Shh for cells endogenous to the cortex and
those that may migrate from the SVZ.
Post-injury, NSCs can arise de novo from endoge-
nous precursors or can migrate into the lesion. For ex-
ample, after an aspiration lesion, DCS+ cells migrate
into the injury site from the SVZ.29 NSCs that migrate
from the SVZ influence the injury microenvironment,
suggesting that these migrating NSCs may stabilize
the injury milieu after injury.13 Their role in limiting
the lesion expansion is well documented because
stem cell ablation induces lesion expansion.8,30,31
Endogenous cells can also contribute to the injury
response and this includes GFAP-expressing cells.
GFAP is well characterized as a marker of radial glia
such as quiescent stem cells, in addition to being a
marker of reactive astrocytes.32,33 Following a CCI,
GFAP+ cells start proliferating34,35 and some of these
cells also express the stem cell progenitor markers nes-
tin and sox2 in addition to the immature neuronal
marker DCX.34,35 This increase in GFAP cells may rep-
resent both reactive astrocytes and an NSC population
because some of these cells are nestin+ and DCX+.
After a cortical stab injury that induces a reactive gliosis,
fate mapping showed that GFAP cells start proliferating
and these cells acquire stem cell-like properties when
cultured in vitro.8 More recently, the same group
showed that the stab incision results in endogenous
NSC activation, due in part to Shh, and this acts directly
on cortical cells leading to increased proliferation.27 We
have demonstrated that in a rodent ex vivo model, en-
dogenous cells are activated after a TBI, display stem
cell-like features when cultured in vitro,12 and their pro-
liferation is affected by modulation of Shh signaling.
We sought to determine if these proliferating cells
expressed other markers of stem cells or progenitor
cells. Although there were too few cells that were nes-
tin+ to correlate any findings to Shh modulation, it
was nevertheless interesting to see nestin expression
within the injured cortex in control and treated animals
because nestin is a well-established NSC marker. At
7 dpi, DCX, an early neuronal marker, was increased
compared with the uninjured contralateral side. A pro-
portion of these cells were newly proliferating because
they were labelled with EdU. Although inhibiting Shh
reduced the number of DCX-labeled cells significantly
at 7 dpi, increasing Shh signaling paradoxically had a
similar effect. This may be explained by the SAG accel-
erating the maturation of the progenitor cells, pushing
them out of a state of immaturity to a mature pheno-
type as indicated by loss of DCX expression,36 or per-
haps even pushing these cells away from a neuronal
phenotype.37
Alternatively, altering the Shh pathway could result in
increased cell death leading to reduced DCX expression.
Although in mammals most DCX+ cells in normal adult
FIG. 6. Activation of Shh signaling with SAG
significantly improves recovery of motor
function after CCI injury. Motor function was
determined by the average time mice could
remain on a rotarod apparatus. Baseline
performance was determined prior to injury
after mice had been acclimatized to the rotarod.
In the control injury group (circle), average
latency was significantly reduced 3 days post-
injury and partially recovered toward baseline
up to 14 days post-injury. A similar pattern was
observed in mice treated with cyclopamine
(triangle), although the recovery was slower,
remaining significantly behind the control group
at 7 dpi. In contrast, mice treated with SAG
(square) showed an enhanced recovery that was
significantly better than control at all three time-
points post-injury and which returned to pre-
injury baseline levels by day 7. (n = 9–10,
**p < 0.01 vs. control; ***p < 0.001 vs. control).
CCI, cortical contusion injury; CYCLO,
cyclopamine; dpi, days post-injury; SAG,
Smoothened agonist; Shh, sonic hedgehog.
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neurogenesis undergo cell death, DCX ablation of the
remaining cells impedes cognitive recovery.38 Further
work should be directed at determining the fate of
these cells in the longer term beyond 7 dpi, for instance
by fate mapping using genetically labeled cells, because
only low numbers of labeled cells were observed using
our current methodology. Others have demonstrated
that GFAP+/sox2+ radial glia cell numbers peak at 3
days following a CCI.35 Although the authors suggest
these cells migrate from the SVZ, they may also arise
from endogenous precursors. Interestingly, retroviral
delivery of transcription factors leads to the conversion
of reactive glia into stem/progenitor cells and subse-
quently into neurons following TBI,39 suggesting that
these cells are amenable to reprogramming. Our studies
do not support the notion that these cells become neu-
rons, as the time course is too short to allow this.
Importantly, the effects of modulating Shh signaling
on cell proliferation correlated with improved motor
recovery. The post-injury rotarod test performance
was significantly improved by SAG treatment. This ef-
fect was significant compared with CCI-control mice at
3 dpi, and the recovery was maintained until 14 dpi. In
contrast, the performance of mice treated with the Shh
inhibitor cyclopamine was indistinguishable from con-
trols after 14 dpi. Therefore, we can infer that increasing
the number of proliferating GFAP+ cells, through activa-
tion of Shh signaling, correlates with improved motor
function. Alternative mechanisms include cell death
resulting in lesion size expansion or direct modulation
of the inflammatory environment by Shh signaling.
The early timing of the motor recovery within days is
unlikely a consequence of neuronal integration-based
recovery. In the early period, the effect is likely to be a
neuroprotective effect of Shh, such as that seen with
other pharmacological agents.40,41 One way to investi-
gate this would be to use a transgenic approach to genet-
ically ablate the progenitors following SAG treatment to
determine if they contribute to the functional improve-
ment observed. Endogenous stem/progenitor cells con-
tribute to functional recovery after several injury
models including TBI. Ablating stem/progenitor cells
migrating from the SVZ reduces the recovery of motor
function following a CCI.13 In a middle cerebral artery
occlusion stroke model, genetic deletion of Shh expres-
sion in nestin-expressing cells led to worsening motor
ability.42 Further, SAG treatment improved both loco-
motor function and cognitive function following
stroke.28 In a nigrostriatal model for neurodegeneration,
transplanted NSCs with silenced Shh signaling impaired
the neuroprotective effects of the NSCs.43 There is there-
fore strong evidence linking activation of Shh signaling
and stem cell activation with improved recovery in sev-
eral models of neural injury and neurodegeneration.
If we are to translate the observations from our ro-
dent studies into patients, whereby increasing Shh
with pharmacological inhibitors could affect endoge-
nous precursors, we need to determine whether Shh
is altered following TBI and also if the human brain
contains the necessary machinery to respond to modu-
lation of Shh signaling. Importantly, in patients with
TBI, we have shown that there is a significant decrease
in Shh in the CSF, although why this occurs is not
known. Our finding suggests an opportunity to in-
crease Shh in CSF through small-cell activators of
Shh signaling. There are known steroid agonists of
Shh signaling, currently in clinical use, which could
be tested.44 Although Shh levels within the parenchyma
of patients with TBI is not known, there is a transient
decrease in Shh protein levels in the rat brain following
a CCI.45 In human cortex, the components of the sig-
naling pathway are equivalent in mRNA expression
compared with the hippocampus, the latter we know
in humans is rich in NSCs.46 Interestingly, it has
been observed that there is an increase in DCX-
expressing cells in brains from TBI patients.47 It
would therefore be useful to investigate the endogenous
progenitor/stem response in patients with TBI, includ-
ing receptor levels, coupled with in vitro human pro-
genitor work to determine if human cells respond to
Shh small-molecule activators. This would begin to an-
swer the key clinical question of whether this treatment
could improve recovery in patients.
Conclusion
We demonstrated that increasing Shh signaling after in-
jury increases the number of newly proliferating cells,
and this is accompanied by improvement in motor func-
tion in rodents. Therefore, we can infer that increasing
the number of proliferating GFAP+ cells (a proportion
of which are progenitor cells) through activation of
Shh signaling offers an avenue to manipulate the niche
environment of the non-permissive injured brain. This
may lead to strategies for endogenous neural repair
and subsequent functional recovery.
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